| Multiple Sclerosis, Relapsing-Remitting
Mayzent vs Vumerity
Side-by-side clinical, coverage, and cost comparison for multiple sclerosis, relapsing-remitting.Deep comparison between: Mayzent vs Vumerity with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVumerity has a higher rate of injection site reactions vs Mayzent based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vumerity but not Mayzent, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Mayzent
Vumerity
At A Glance
Oral
Daily
S1P receptor modulator
Oral
Twice daily
Nrf2 pathway activator
Indications
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- active secondary progressive multiple sclerosis
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
Dosing
Clinically isolated syndrome, Multiple Sclerosis, Relapsing-Remitting, active secondary progressive multiple sclerosis 2 mg orally once daily (CYP2C9 *1/*1, *1/*2, or *2/*2) or 1 mg orally once daily (CYP2C9 *1/*3 or *2/*3), each initiated with a dose titration regimen; administer tablets whole, do not split, crush, or chew.
Clinically isolated syndrome, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive Starting dose 231 mg twice daily orally for 7 days; maintenance dose 462 mg (two 231 mg capsules) twice daily orally; temporary reduction to 231 mg twice daily may be considered for tolerability, resuming 462 mg twice daily within 4 weeks.
Contraindications
- CYP2C9 *3/*3 genotype
- Myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III or IV heart failure within the last 6 months
- Mobitz type II second-degree, third-degree AV block, or sick sinus syndrome without a functioning pacemaker
- Known hypersensitivity to diroximel fumarate, dimethyl fumarate, or any excipient of VUMERITY (reactions may include anaphylaxis and angioedema)
- Concomitant use of dimethyl fumarate
Adverse Reactions
Most common (>=10%) headache, hypertension, transaminase increased
Serious infections, progressive multifocal leukoencephalopathy, macular edema, bradyarrhythmia and AV conduction delays, liver injury, cutaneous malignancies, posterior reversible encephalopathy syndrome, fetal risk
Postmarketing progressive multifocal leukoencephalopathy
Most common (>=10%) Flushing, abdominal pain, diarrhea, nausea
Serious Anaphylaxis, angioedema, progressive multifocal leukoencephalopathy, herpes zoster and other serious opportunistic infections, lymphopenia, liver injury, serious gastrointestinal reactions
Postmarketing Acute pancreatitis, gastrointestinal perforation/ulceration/obstruction/hemorrhage, liver function abnormalities (transaminases >=3 times ULN with total bilirubin >2 times ULN), herpes zoster infection, rhinorrhea, alopecia
Pharmacology
Siponimod is an S1P receptor modulator that binds with high affinity to S1P receptors 1 and 5, blocking lymphocyte egress from lymph nodes and reducing peripheral blood lymphocyte counts; the therapeutic mechanism in multiple sclerosis is unknown but may involve reduction of lymphocyte migration into the central nervous system.
Diroximel fumarate is a prodrug converted to its active metabolite monomethyl fumarate (MMF), which activates the Nrf2 pathway involved in cellular response to oxidative stress and acts as a nicotinic acid receptor agonist in vitro; the mechanism by which it exerts therapeutic effect in multiple sclerosis is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Mayzent
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (9/12)
Vumerity
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (10/12)
UnitedHealthcare
Mayzent
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (4/8)
Vumerity
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Mayzent
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Vumerity
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
MayzentView full Mayzent profile
VumerityView full Vumerity profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.